Manufacturing, Biologic Drugs

Lonza, Humanigen Partner to Expand Manufacturing of Lenzilumab for Potential COVID-19 Therapy

September 18, 2020

The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.

Novavax in COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India

September 18, 2020

The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.

Lilly and Amgen in Manufacturing Collaboration for COVID-19 Antibody Therapies

September 18, 2020

The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.

Cytiva Invests $500 Million Over 5 years to Expand Global Capacity

September 14, 2020

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

MilliporeSigma Invests $65 Million to Expand Antibody-Drug Conjugate Manufacturing

September 09, 2020

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

Catalent Invests $130 Million to Expand Gene Therapy Manufacturing Capacity

September 09, 2020

The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.

Preparing Pandemic Vaccine Capacity

September 03, 2020

Rapid scale-up to billions of doses requires collaborative, all-out efforts by innovators, their manufacturing partners, and the entire supply chain.

HJB and Ansun Biopharma Partner on Biologics CMC Development and Manufacturing

September 02, 2020

The companies have entered into a strategic partnership for the CMC development and manufacturing of Ansun’s biologics pipeline.

iBio and Planet Biotechnology Partner to Develop COVID-19 Therapeutic

September 02, 2020

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

Catalent to Manufacture Drug Substance for AstraZeneca’s COVID-19 Vaccine Candidate

August 24, 2020

Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.